To date, no clinically relevant events have been reported that argue against a mistletoe therapy for cancer treatment during COVID-19 disease. However, no systematic studies of mistletoe therapy in cancer patients with confirmed SARS-CoV-2 infection or with COVID-19 disease are available at this time. Mistletoe therapy is not indicated in the hyperinflammatory phase of the COVID-19 disease. For cancer patients with long COVID syndrome, mistletoe therapy is discussed as a supportive agent.
Cancer patients who want to be vaccinated against COVID-19 are advised to discontinue mistletoe therapy three days before the planned vaccination date. Even in the absence of a vaccination reaction, it is recommended to continue mistletoe therapy one week after COVID-19 vaccination. If vaccination reactions occur, a "mistletoe pause" is indicated until acute symptoms have subsided.
Last update: April 28th, 2021/ AT